Clinical-epidemiological characteristics of COVID-19 in the high-altitude population of Perú
DOI:
https://doi.org/10.53732/rccsalud/2023.e5110Keywords:
coronavirus, epidemiology, population, SARS-CoV-2, COVID-19Abstract
Introduction: COVID-19 has shown great clinical and epidemiological variability. Objective: The aim of this study was to describe the sociodemographic and clinical-epidemiological characteristics of COVID-19 in a high-altitude population of Perú. Materials and methods: Observational and retrospective study. The population consisted of ambulatory patients diagnosed with COVID-19 from a primary care health facility located at an altitude of 3850 meters above sea level. Documentary analysis of medical records was carried out. Data analysis was descriptive in terms of percentages and measures of central tendency. Results: The study included 154 patients, mostly female (56.5%), adults (51.3%), and housewives (37.0%). The most frequent and longest-lasting symptoms were cough (80.5%, 6.3 days), sore throat (61.7%, 3.6 days), and headache (58.4%, 3.5 days). The most common clinical classification was mild (69.5%). The most common comorbidities were pregnancy (14.5%), hypertension (8.25%), and obesity (5.5%). Oxygen saturation in the elderly was on average the lowest (84.5), while in adolescents it was on average the highest (90). Conclusion: Women, adult housewives, and those with comorbidities such as pregnancy, hypertension, and obesity were most affected. The most frequent and longest-lasting symptoms were cough, sore throat, and headache. Oxygen saturation decreased with age.
References
Organización Mundial de la Salud. Brote de coronavirus (COVID-19). 2020. https://www.who.int/westernpacific/emergencies/covid-19
Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2023. https://coronavirus.jhu.edu/map.html
Ministerio de Salud del Perú. Situación del COVID-19. 2023. https://www.dge.gob.pe/portalnuevo/covid-19/covid-cajas/situacion-del-covid-19-en-el-peru/
Ministerio de Salud del Perú. Sala situacional COVID 19 Perú. 2022. https://covid19.minsa.gob.pe/sala_situacional.asp
OMS. (19 de febrero del 2022). Informacion Basica Sobre el COVID 19. 2022. https://www.who.int/es/news-room/questions-and-answers/item/coronavirus-disease-covid-19
INEI. Peru: Enfermedades no transmisibles y transmisibles 2020. 2020. https://proyectos.inei.gob.pe/endes/2020/SALUD/ENFERMEDADES_ENDES_2020.pdf pe)
Gonzales GF. Hemoglobin and testosterone: Importance on high altitude acclimatization and adaptation. Rev Peru Med Exp Salud Publica. 2011;28(1):92-100. 10.1590/s1726-46342011000100015
Diaz Lazo AV, Montalvo Otivo R, Lazarte Nuñez E, Aquino Lopez E. Caracterización clínica y epidemiológica de los pacientes con COVID-19 en un hospital situado en la altura. Horiz Médico. 2021;21(2):e1303. https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/1303
Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr Clin Res Rev. julio de 2020;14(4):283-7. https://linkinghub.elsevier.com/retrieve/pii/S1871402120300564
Nematollahi S, Shariatpanahi S, Hosseini MR, Fatemi A. Why are Men more susceptible to COVID-19: A narrative review of current global knowledge. Men’s Heal J. 2020;4(1):e1. https://journals.sbmu.ac.ir/mhj/article/view/29811
Ruiz-Nápoles J, Ruiz-Nápoles K. Pacientes asintomáticos positivos a la COVID-19. Rev Cuba Med Mil. 2021;50(1):1-11. http://www.revmedmilitar.sld.cu/index.php/mil/article/view/893
Moreno Tetlacuilo LMA, Gutiérrez Juárez K. Hombres, mujeres y la COVID-19. ¿Diferencias biológicas, genéricas o ambas?..-Univ Nac Autónoma México Boletín sobre COVID-19. 2020;1(6):3-6. https://dsp.facmed.unam.mx/wp-content/uploads/2022/03/COVID-19-No.6-03-Hombres-mujeres-y-la-COVID-19.pdfam.mx)
Ospina C, Volcy M. Enfoque del paciente con cefalea en tiempos de covid-19. Acta Neurológica Colomb. 2020;36(2 Supl. 1):27-38. 10.22379/24224022291
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://linkinghub.elsevier.com/retrieve/pii/S0140673620301835
Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954-76. 10.1016/S1474-4422(18)30322-3
Özceylan G, Altuntaş SB. Relationship between initial symptoms and prognosis of patients with Covid-19. Aten Primaria. 2022;54(1):102146. 10.1016/j.aprim.2021.102146
Pérez Padilla JR, Thirión Romero II, Aguirre Pérez T, Rodríguez Llamazares S. ¿Qué tan silenciosa es la hipoxemia en COVID-19? NCT Neumol y Cirugía Tórax. 2020;79(2):69-70. 10.35366/94629
Coen M, Allali G, Adler D, Serratrice J. Hypoxemia in COVID‐19; Comment on: “The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients”. J Med Virol. 2020;92(10):1705-6. 10.1002/jmv.26020
Saldías Peñafiel F, Peñaloza Tapia A, Farías Nesvadba D, Farcas Oksenberg K, Reyes Sánchez A, Cortés Meza J, et al. Manifestaciones clínicas y predictores de gravedad en pacientes adultos con infección respiratoria aguda por coronavirus SARS-CoV-2. Rev Med Chil. 2020;148(10):1387-97. http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020001001387&lng=en&nrm=iso&tlng=en
Of NI, Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2019. https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/
Accinelli RA, Zhang Xu CM, Ju Wang J-D, Yachachin-Chávez JM, Cáceres-Pizarro JA, Tafur-Bances KB, et al. COVID-19: La pandemia por el nuevo virus SARS-CoV-2. Rev Peru Med Exp Salud Publica. 2020;37(2):302-11. https://www.scielosp.org/article/rpmesp/2020.v37n2/302-311/
Accinelli RA, Leon-Abarca JA. En la altura la COVID-19 es menos frecuente: la experiencia del Perú. Arch Bronconeumol. 2020;56(11):760-1. 10.1016/j.arbres.2020.06.015
Cardona Rivero A, Montoya M. Covid19 en población residente de zonas geográficas a alturas superiores a 2500 m.s.n.m. SITUA. 2020;23(1):16. 10.51343/si.v23i1.204
Chung Ming Chu, Leo L.M. Poon, Vincent C.C. Cheng, Kin Sang Chan, Ivan F.N. Hung, Maureen M.L, et al. Initial viral load and the outcomes of SARS. Can Med Assoc J. 2004;171(11):1349-52. 10.1503/cmaj.1040398
Tejada López Y, Goicochea Ríos E del S, Guzmán Aybar OY. Clinical epidemiological characteristics of patients diagnosed with SARS-CoV-2. Hospital I Florencia de Mora EsSalud – La Libertad, 2020. Rev la Fac Med
Humana. 2021;21(4):696-703. 10.25176/RFMH.v21i4.3609
Liu H, Wang L-L, Zhao S-J, Kwak-Kim J, Mor G, Liao A-H. Why are pregnant women susceptible to COVID-19? An immunological viewpoint. J Reprod Immunol. 2020;139:103122. 10.1016/j.jri.2020.103122
Aguirre G, Urquieta C, Chavez E, Perez Y, Tarqui BA, Patón D, et al. Alteraciones hematológicas en gestantes con covid-19 residentes en la altura. Rev Méd La Paz; 2021; 27(1):15-20. http://scielo.org.bo/scielo.php?script=sci_arttext&pid=s1726-89582021000100003
Sola A, Rodríguez S, Cardetti M, Dávila C. COVID-19 perinatal en América Latina. Rev Panam Salud Pública. 2020;44:1. 10.26633/RPSP.2020.47
Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19):1801-3. 10.1093/eurheartj/ehaa235
Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-8. 10.1007/s00392-020-01626-9
.png)
All the contents of this journal are licensed under a 